In the context of inflammation, autoimmune diseases, infections, and cancers, cfDNA plays a pivotal role in disease progression through various mechanisms. Immunotherapies based on cfDNA scavenging has emerged as a promising approach for treating these conditions. This review offers a comprehensive exploration of cfDNA-binding and degradation strategies, providing detailed insights into the corresponding nano/microsystems for each approach. Nano/microsystems used for cfDNA binding include cationic polymers, nanoparticles, nanogels, and other materials that physically capture cfDNA via electrostatic interactions or other affinity mechanisms, thereby mitigating the immunological effects of cfDNA. Nano/microsystems designed for cfDNA degradation primarily involve DNase delivery systems and artificial enzymes with DNase-like activity, which degrade cfDNA through chemical cleavage. Furthermore, this review discusses the potential synergy between cfDNA-scavenging therapies and other treatment modalities, aiming to achieve more effective and comprehensive immunotherapy. By thoroughly analyzing these strategies, we aim to emphasize the transformative potential of cfDNA-scavenging nano/microsystems in advancing immunotherapy, and offer valuable perspectives for future research in this emerging field.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jconrel.2025.113609 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Biomimetic Sweeping Microrobot for Active Therapy of Ulcerative Colitis.
Adv Mater
March 2025
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Overproduction of pathogenic cell-free DNA (cfDNA) and reactive oxygen species (ROS) plays crucial roles in the onset and perpetuation of ulcerative colitis (UC). Inspired by sweeping robots, a magnesium@polylactic acid-glycolic acid copolymer@polyethylenimine (Mg@PLGA@PEI) microswimmer capable of cleaning off deleterious disease triggers along its path of progress is designed. Mg@PLGA@PEI is successfully synthesized by adopting a core-shell structure with a small opening which allows for Mg-water reaction.
View Article and Find Full Text PDFEstablishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium.
Clin Transl Sci
March 2025
BLOODPAC, Chicago, Illinois, USA.
The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis of circulating tumor DNA (ctDNA) are rapidly evolving for clinical study applications and therapeutic interventions.
View Article and Find Full Text PDFCirculating tumor DNA in lymphoma: technologies and applications.
J Hematol Oncol
March 2025
Department of Hematology, The First Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China.
Lymphoma, a malignant tumor derived from lymphocytes and lymphoid tissues, presents with complex and heterogeneous clinical manifestations, requiring accurate patient classification for appropriate treatment. While invasive pathological examination of lymph nodes or lymphoid tissue remains the gold standard for lymphoma diagnosis, its utility is limited in cases of deep-seated tumors such as intraperitoneal and central nervous system lymphomas. In addition, biopsy procedures carry an inherent risk of complications.
View Article and Find Full Text PDFThe diagnostic accuracy of preimplantation genetic testing (PGT) in assessing the genetic status of embryos: a systematic review and meta-analysis.
Reprod Biol Endocrinol
March 2025
Department of Reproductive Medicine, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, First People's Hospital of Yunnan Province, Kunming, 650500, China.
Background: Preimplantation genetic testing (PGT) is widely used in assisted reproduction to assess the genetic status of embryos. However, increasing evidence suggests that the trophectoderm (TE) may not fully reflect the genetic status of the inner cell mass (ICM), raising controversy about the accuracy of TE biopsy. Research in recent years has focused on cell-free DNA (cfDNA) found in blastocoel fluid (BF) and spent culture medium (SCM), as these may contain genetic information from both the TE and ICM.
View Article and Find Full Text PDFMultimodal integration of liquid biopsy and radiology for the noninvasive diagnosis of gallbladder cancer and benign disorders.
Cancer Cell
March 2025
Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; Shanghai Key Laboratory of Systems Regulation and Clinical Translation for Cancer, Shanghai 200127, China; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai 200127, China. Electronic address:
Gallbladder cancer (GBC) frequently mimics gallbladder benign lesions (GBBLs) in radiological images, leading to preoperative misdiagnoses. To address this challenge, we initiated a prospective, multicenter clinical trial (ChicCTR2100049249) and proposed a multimodal, non-invasive diagnostic model to distinguish GBC from GBBLs. A total of 301 patients diagnosed with gallbladder-occupying lesions (GBOLs) from 11 medical centers across 7 provinces in China were enrolled and divided into a discovery cohort and an independent external validation cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!